{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 46 of 92', 'CR845-CLIN3103', '6.5.2', 'Schedule of Events for the Open-label Extension Phase', 'Study procedures for the Open-label Extension Phase are summarized in Table 3.', 'The safety assessment visit may occur on any chosen dialysis day of a scheduled week as', 'long as all assessments are completed during that visit. Patients who miss one of the', 'scheduled study visit weeks (eg, Week 4 of open-label treatment) may complete this visit', 'at their next dialysis treatment if conducted within 2 weeks of the scheduled visit.', 'Unscheduled visits may be necessary for outstanding, unresolved adverse events', '(eg, additional safety laboratory or clinical evaluations). At minimum, for any', 'unscheduled visit, the reason for the visit will be recorded, the adverse events reported, as', 'well as changes to concomitant medications, as applicable. Additional testing', '(eg, laboratory tests, vital signs, ECGs) will be performed as clinically indicated.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 47 of 92', 'CR845-CLIN3103', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', 'Open-label Treatment Period Up to 52 Weeks of Dosing', 'Follow-Up Period', 'First Dialysis of', 'Week 53b', '7 - 10 days after End of', 'End of Treatment', 'Treatment/Early', 'Termination', 'Study Procedures', 'Day 1\u00b0', 'Week 4', 'Week 8', 'Week 12', 'Week 24', 'Week 36a', '/Early Termination', 'Administrative procedures', 'Inclusion/exclusion criteria', 'Xd', 'Safety and other evaluations', 'Physical examination', 'X', 'Record prescription dry body weighte', 'Xe', 'Record every 12 weekse', 'Pre-dialysis 12-lead electrocardiogram\u00b2', 'X', 'Pre-dialysis vital signs.', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Hematology, serum chemistry', 'X', 'X', 'X', '(pre-dialysis)', 'Serum pregnancy test for women of', 'X', 'X', 'X', 'childbearing potential only', 'Record number of missed dialysis visits', 'and reason(s), as applicable', 'Record on an ongoing basis', 'IV administration of study drug', 'Xh', 'Dose after each dialysis up to Week 52 included', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 48 of 92', 'CR845-CLIN3103', 'Table 3.', 'Schedule of Events: Open-label Extension Phase', '(Continued)', 'Open-label Treatment Period Up to 52 Weeks of Dosing', 'Follow-Up Period', 'First Dialysis of Week', '53b', '7 - 10 days after End of', 'Treatment/Early', 'End of Treatment /Early', 'Termination', 'Study Procedures', 'Day 1\u00b0', 'Week 4a', 'Week 8', 'Week 12a', 'Week 24', 'Week 36a', 'Termination', 'Safety and other evaluations', '5-D itch scale\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', 'Inflammatory biomarker samples\u00b9', 'X', 'X', 'Adverse event monitoring', 'Record on an ongoing basis*', 'Concomitant medications (including', 'antipruritic medications)', 'Record on an ongoing basis*', 'IV = intravenous', 'a.', \"Each visit during the Open-label Treatment Period will coincide with the patient's normal dialysis treatments. The study visit may occur on any chosen dialysis day of a\", 'scheduled week as long as all assessments are completed during that visit. However, it is recommended to avoid the first dialysis day of the week. Patients who miss one of', 'the scheduled study visit weeks (eg, Week 4) may complete the visit procedures for this visit at their next dialysis treatment as long as it is within 2 weeks of the originally', 'scheduled visit date.', 'b. The End-of-Treatment Visit will be the first dialysis visit following the last dose of study drug (ie, first dialysis on Week 53).', 'c.', 'Day 1 of the Open-label Extension Phase can occur immediately on the day of the last visit of the Double-blind Treatment Period or up to 1 week following the Double-blind', 'Treatment Period.', 'd. Prior to dosing on Day 1 of the Open-label Extension Phase, the inclusion/exclusion criteria will be confirmed.', 'e.', 'The prescription dry body weight will be captured from the dialysis prescription and will be recorded on Day 1 and every 12 weeks during the Open-label Treatment Period', '(during Weeks 12, 24, 36, and 48). If there is a 10% or more change in prescription dry body weight compared to the dry body weight recorded at screening, then the', 'CR845 dose will be adjusted according to the newly recorded dry body weight. The date of prescription dry body weight change will also be recorded.', 'f.', 'Electrocardiogram must be performed prior to the start of dialysis.', 'g.', 'Vital signs, including body temperature, heart rate, and blood pressure, will be obtained at the specified visits while the patient is in a sitting or semi-recumbent position prior', 'to the start of dialysis. Heart rate will be measured at each dialysis; if the heart rate is clinically significant and outside the prespecified visits per the Schedule of Events the', 'heart rate will be recorded on the relevant CRF page.', 'h.', 'Administered after each dialysis as an IV bolus.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}